Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
344 Leser
Artikel bewerten:
(1)

EuroMinnie 2021 Award: ImageBiopsy Lab is the "Best New Radiology Vendor"

VIENNA, March 2, 2021 /PRNewswire/ -- ImageBiopy Lab has been selected "Best New Radiology Vendor" for 2021 by AuntMinnieEurope.com, the European version of the highly influential AuntMinnie.com radiology professional community.

The ImageBiopsy Lab Management Team

This award is a significant recognition for ImageBiopsy Lab, a Vienna-based AI-solution developer that has pioneered digital transformation in the field of musculoskeletal (MSK) radiology.

Dr. Richard Ljuhar, CEO and Co-Founder of ImageBiopsy Lab: "Understanding the diagnostic workflow and needs of physicians are the key elements before even starting to think of the use of AI. For years now, we have been working closely with leading MSK radiologists, orthopedics and traumatologists to not just understand how AI can play a role in MSK diagnostics, but also to discover how solutions can be seamlessly integrated into existing workflows. We have made it our vision to transform the entire diagnostic MSK value chain for the benefit of practitioners, patients and the overall healthcare system."

ImageBiopsy Labs' CE and FDA certified AI-driven software applications digitize MSK diagnostics on radiographs, providing radiologists and orthopedics with fast, quantitative and standardized reporting. The company portfolio already includes solutions for knee, hip, hand and spine and is being installed at more than 100 sites across Europe and the US.

ImageBiopsy Lab is focused on expanding its offerings in the US MSK market following their first-of-its-kind FDA clearance of an AI MSK radiology solution for detecting radiographic signs of knee osteoarthritis - IB Lab KOALA. The team has plans for additional FDA clearances of their existing portfolio in 2021 and is also working to bring their unique brand of AI-automation to additional anatomical regions, diagnostic use cases and imaging formats.

The "Awards for Excellence in Radiology" is held by AuntMinnieEurope.com - an influential European community for radiologists and related professionals in the medical imaging industry. The full list of EuroMinnie candidates came from nominations submitted in late 2020 by members of AuntMinnieEurope.com. Winners in each category were selected by a panel of radiology luminaries comprising members of the editorial advisory board, past recipients, and regular columnists.

About ImageBiopsy Lab:

ImageBiopsy Lab, the Vienna-based MSK AI-solution developer was founded as a spin off in late 2016. The company develops and offers award-winning AI-driven software applications that digitize musculoskeletal (MSK) diagnostics on radiographs, providing radiologists and orthopedics with fast, quantitative and standardized reports of disease relevant findings and measurements. Today, ImageBiopsy Lab has offices in the EU and the US and brings together an interdisciplinary, international team of physicians, clinical researchers and software experts, sharing the passion for having a lasting and meaningful impact on digital healthcare.

Photo - https://mma.prnewswire.com/media/1448073/Image_Biopsy_Lab.jpg
Logo - https://mma.prnewswire.com/media/1448072/Image_Biopsy_Lab_Logo.jpg

Image Biopsy Lab Logo

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.